首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1610890

分子診斷:市場洞察·競爭環境·市場預測 (～2030年)

Molecular Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年12月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

分子診斷市場規模預計將從 2023 年的 95.6 億美元成長到 2030 年的 161.2 億美元，預測期內複合年增長率為 9.21%。

由於愛滋病毒、B型肝炎、C型肝炎、流感和人類乳突病毒 (HPV) 等傳染病患者數量的增加，以及創新新產品的推出，分子診斷市場正在經歷顯著增長。這些因素將在2024 年至2030 年繼續推動市場發展。

分子診斷：市場動態

根據世界衛生組織 (WHO) 2024 年的公告，到 2022 年，全球將有約 3,900 萬人感染愛滋病毒。約 3,750 萬人是成年人（15 歲或以上），約 150 萬人是 15 歲以下的兒童。分子診斷對於早期檢測 HIV、監測病毒量和識別抗藥性突變至關重要。這些測試可以幫助評估治療效果、指導治療決策並預防傳播，特別是在兒童和成人等弱勢群體中。

根據世界衛生組織2024年數據，2022年全球B型肝炎和C肝感染人數預計為3.04億人。其中，據稱有 2.54 億人感染B型肝炎，5,000 萬人感染C型肝炎。分子診斷透過早期準確地識別病毒感染，在B型肝炎和C型肝炎的檢測和管理中發揮重要作用。 PCR 等技術用於檢測血液樣本中的病毒 DNA 和 RNA，使臨床醫生能夠確認活動性感染、監測病毒量並評估治療效果。

所有這些因素預計將在預測期內推動市場發展。

本報告提供全球分子診斷的市場調查，彙整市場概要，市場影響因素及市場機會分析，法律制度，市場規模的轉變·預測，各種區分·地區/各主要國家的詳細分析，競爭情形，主要企業簡介等資訊。

各產品類型
- 設備
- 試劑
- 其他
各技術
- 聚合酵素鏈鎖反應 (PCR)
- 定序
- 界內犀牛親嘴雜合反應
- 微陣列分析
各用途
- 感染疾病診斷
- 腫瘤學研究
- 遺傳基因研究
各終端用戶
- 醫院
- 病理實驗室
各地區
- 北美
- 歐洲
- 亞太地區
- 其他地區

第8章分子診斷市場:企業·產品簡介

F. Hoffmann-La Roche Ltd.
Hologic, Inc.
bioMerieux SA
Abbott
QIAGEN
BD
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Danaher
Myriad Genetics, Inc.
Agilent Technologies Inc.
Illumina Inc.
DiaSorin Inc.
MDxHealth
Genetic Signatures
Biocartis
Exact Sciences Corporation
Amoy Diagnostics Co. Ltd.
Molbio Diagnostics Pvt. Ltd.
Savyon Diagnostics

第9章 KOL的見解

第10章計劃的方法

第11章關於DelveInsight

第12章免責聲明·聯絡方式

簡介目錄圖表

Product Code: DIMDCL0469

Molecular Diagnostic Market by Product Type (Instruments, Reagents, and Others), Technology (Polymerase Chain Reaction [PCR], Next Generation Sequencing, In-Situ Hybridization, Microarray Analysis, and Others), Application (Infectious Disease Diagnosis, Oncology Testing, Genetic Testing, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of infectious diseases and the rising product developmental activities worldwide

The molecular diagnostics market was valued at USD 9.56 billion in 2023, growing at a CAGR of 9.21% during the forecast period from 2024 to 2030, to reach USD 16.12 billion by 2030. The molecular diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B and C, influenza, and human papillomavirus (HPV), introduction of new and innovative products by key players, among others is expected to drive the market for molecular diagnostics from 2024 to 2030.

Molecular Diagnostics Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years. Molecular diagnostics is essential in HIV for early detection, monitoring viral load, and identifying drug resistance mutations. These tests help assess treatment efficacy, guide therapy decisions, and prevent transmission, particularly in vulnerable populations like children and adults.

Data from the WHO 2024, stated that 304 million people were infected by hepatitis B and C across the world in the year 2022. The same source further stated that out of these, 254 million were afflicted by hepatitis B and 50 million were affected by hepatitis C. Molecular diagnostics play a critical role in the detection and management of hepatitis B and C by allowing for early and accurate identification of viral infections. Techniques such as PCR are used to detect viral DNA or RNA in blood samples, enabling clinicians to confirm active infections, monitor viral load, and assess the effectiveness of treatment.

Additionally, the introduction of new and innovative products by key players are pushing forward the market share for same. For example, in November 2023, Roche announced the launch of the LightCycler PRO System. The LightCycler PRO System further complemented Roche's molecular PCR testing portfolio.

Hence, the interplay of all the above-mentioned factors is expected to drive the molecular diagnostics market during the given forecast period from 2024 to 2030.

However, the availability of alternative diagnostic methods, high cost associated with molecular diagnostic procedures, among others may restrict the market growth for the molecular diagnostics market.

Molecular Diagnostics Market Segment Analysis:

Molecular Diagnostic Market by Product Type (Instruments, Reagents and Others), Technology (Polymerase Chain Reaction [PCR], Next Generation Sequencing, In-Situ Hybridization, Microarray Analysis, and Others), Application (Infectious Disease Diagnosis, Oncology Testing, Genetic Testing, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the molecular diagnostics market, the PCR category is expected to have a significant revenue share in the year 2023. The rapid growth of this category can be attributed to the various features and applications of PCR in diagnostics.

PCR is a cornerstone of molecular diagnostics due to its precision, sensitivity, and versatility. It enables the amplification of specific DNA or RNA sequences, allowing for the detection of minute amounts of genetic material. Key features include its rapidity and ability to produce millions of copies of target sequences in a short time, making it highly useful in diagnosing infectious diseases, genetic disorders, and cancer.

PCR's accuracy stems from its specificity, as primers are designed to bind only to particular sequences, reducing false positives. Its sensitivity allows detection even at very low levels of pathogens or mutations. Real-time PCR (qPCR) extends these benefits by providing quantitative data, enabling not just the detection but also the measurement of viral or bacterial load. PCR-based diagnostics are widely used in virology, including for diseases such as COVID-19, HIV, and hepatitis. Additionally, PCR plays a crucial role in oncology for identifying gene mutations and translocations, and in genetic testing for inherited diseases. It is also applied in prenatal testing, food safety, and forensic analysis.

Therefore, owing to the above-mentioned factors, the demand for the PCR category upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the molecular diagnostics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall molecular diagnostics market:

Among all the regions, North America is estimated to hold a significant revenue share in the molecular diagnostics market. This domination is due to the growing burden of cancer cases in the region, rise in infectious disease instances including tuberculosis, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the molecular diagnostic market in the region during forecast period from 2024 to 2030.

Global Cancer Observatory (2024), estimated that 3.83 million new case of cancer will be diagnosed by 2045 in North American region. Molecular diagnostics are used to detect genetic mutations, guide personalized treatments, and monitor disease progression through methods like liquid biopsy and companion diagnostics.

Public Health Agency of Canada (2024), stated that in 2022, there were 1,971 active tuberculosis cases in Canada. In tuberculosis, molecular diagnostics enable rapid and accurate identification of mycobacterium tuberculosis, as well as the detection of drug resistance, improving timely diagnosis and treatment.

Molecular diagnostics enhance precision in both disease detection and treatment selection, ultimately improving patient outcomes. Additionally, the presence of key manufacturers in the region and their strategic business activities will also contribute to the molecular diagnostic market growth.

Rising product developmental activities by regulatory bodies in the region are likely to push forward the revenue shares for same. For example, in November 2023, Abbott announced that it received the U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution.

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the molecular diagnostics market during the forecast period from 2024 to 2030.

Molecular Diagnostics Market key players:

Some of the key market players operating in the molecular diagnostics market include Hoffmann-La Roche Ltd., Hologic, Inc., bioMerieux SA, Abbott, QIAGEN, BD, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Myriad Genetics, Inc., Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., MDxHealth, Genetic Signatures, Biocartis, Exact Sciences Corporation, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and others.

Recent Developmental Activities in the Molecular Diagnostics Market:

In April 2024, Speedx Pty Ltd. launched the new rapid polymerase chain reaction (qPCR) test for 14 different respiratory viruses in a single test that worked on almost every commercial PCR platform in less time and at a reduced cost.
In November 2021, Roche launched the cobas(R) 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.
In October 2021, Hologic launched its molecular diagnostic system, Novodiag, for on-demand molecular testing in Europe. The system combined real-time polymerase chain reaction (PCR) with microarray capabilities to enable the identification of multiple pathogens in a single sample.
In March 2021, Materials and Machines Corporation (MatMaCorp) introduced its new handheld device MY Real-Time Analyzer (MYRTA), which could carry out polymerase chain reaction (PCR) amplification and real-time fluorescent detection.

Key takeaways from the Molecular Diagnostics market report study

Market size analysis for current molecular diagnostics market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the molecular diagnostics market
Various opportunities available for the other competitors in the molecular diagnostics market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current molecular diagnostics market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for molecular diagnostics market growth in the coming future?

Target audience who can be benefited from this molecular diagnostics market report study

Molecular diagnostics device providers
Research organizations and consulting companies
Molecular diagnostics related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in molecular diagnostics
Various end-users who want to know more about the molecular diagnostics market and the latest developments in the molecular diagnostics market

Frequently Asked Questions for the Molecular Diagnostics Market:

1. What are Molecular Diagnostics?

Molecular diagnostics tests use highly sensitive and specific laboratory methods to detect and identify biomarkers at the nucleic acid (DNA and RNA) level. Typical molecular-based applications include medical diagnosis, prognosis, disease monitoring, and optimal treatment.

2. What is the market for Molecular Diagnostics?

The molecular diagnostics market was valued at USD 9.56 billion in 2023, growing at a CAGR of 9.21% during the forecast period from 2024 to 2030, to reach USD 16.12 billion by 2030.

3. What are the drivers for the Molecular Diagnostics market?

The molecular diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B and C, influenza, and human papillomavirus (HPV), introduction of new and innovative products by key players, among others that are expected to drive substantial demand for molecular diagnostics from 2024 to 2030.

4. Who are the key players operating in the Molecular Diagnostics market?

Some of the major market key players operating in the molecular diagnostics market include Hoffmann-La Roche Ltd., Hologic, Inc., bioMerieux SA, Abbott, QIAGEN, BD, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Myriad Genetics, Inc., Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., MDxHealth, Genetic Signatures, Biocartis, Exact Sciences Corporation, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and others.

5. Which region has the highest share in the Molecular Diagnostics market?

Among all the regions, North America is estimated to hold a significant revenue share in the molecular diagnostics market. This domination is due to the growing burden of cancer cases, rise in infectious diseases including tuberculosis, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the molecular diagnostic market in the region during forecast period from 2024 to 2030.

1. Molecular Diagnostics Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Molecular Diagnostics Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Molecular Diagnostics Market Key Factors Analysis

5.1. Molecular Diagnostics Market Drivers
- 5.1.1. Increasing cases of infectious diseases and chronic disorders
- 5.1.2. Rising product developmental activities
5.2. Molecular Diagnostics Market Restraints and Challenges
- 5.2.1. Availability of alternative diagnostic methods
- 5.2.2. High cost associated with molecular diagnostic procedures
5.3. Molecular Diagnostics Market Opportunities
- 5.3.1. Integration of AI and ML associated with enhanced data interpretation

6. Molecular Diagnostics Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Molecular Diagnostics Market Assessment

7.1. By Product Type
- 7.1.1. Instruments
- 7.1.2. Reagents
- 7.1.3. Others
7.2. By Technology
- 7.2.1. Polymerase Chain Reaction (PCR)
- 7.2.2. Sequencing
- 7.2.3. In Situ Hybridization
- 7.2.4. Microarray Analysis
- 7.2.5. Others
7.3. By Application
- 7.3.1. Infectious Disease Diagnosis
- 7.3.2. Oncology Testing
- 7.3.3. Genetic Testing
- 7.3.4. Others
7.4. By End-User
- 7.4.1. Hospitals
- 7.4.2. Pathology Labs
- 7.4.3. Others
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.1.2. Canada Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.1.3. Mexico Molecular Diagnostics Market Size in USD million (2021-2030)
- 7.5.2. Europe
  - 7.5.2.1. France Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.2.2. Germany Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.2.3. United Kingdom Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.2.4. Italy Molecular Diagnostics market size in USD million (2021-2030)
  - 7.5.2.5. Spain Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.2.6. Rest of Europe Molecular Diagnostics Market Size in USD million (2021-2030)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.3.2. Japan Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.3.3. India Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.3.4. Australia Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.3.5. South Korea Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.3.6. Rest of Asia-Pacific Molecular Diagnostics Market Size in USD million (2021-2030)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.4.2. Africa Molecular Diagnostics Market Size in USD million (2021-2030)
  - 7.5.4.3. South America Molecular Diagnostics Market Size in USD million (2021-2030)

8. Molecular Diagnostics Market Company and Product Profiles

8.1. F. Hoffmann-La Roche Ltd.
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Hologic, Inc.
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. bioMerieux SA
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. Abbott
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. QIAGEN
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. BD
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Thermo Fisher Scientific Inc.
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. Siemens Healthineers AG
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Danaher
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. Myriad Genetics, Inc.
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Agilent Technologies Inc.
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. Illumina Inc.
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. DiaSorin Inc.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. MDxHealth
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Genetic Signatures
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. Biocartis
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Exact Sciences Corporation
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. Amoy Diagnostics Co. Ltd.
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Molbio Diagnostics Pvt. Ltd.
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. Savyon Diagnostics
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy